Cambridge Investment Research Advisors, Inc. Xeris Biopharma Holdings, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 34,642 shares of XERS stock, worth $320,092. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,642
Previous 34,542
0.29%
Holding current value
$320,092
Previous $190,000
14.74%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XERS
# of Institutions
212Shares Held
90MCall Options Held
81.6KPut Options Held
57.6K-
Black Rock Inc. New York, NY10.3MShares$95.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$90.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$35.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$35 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$33.7 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $1.26B
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...